Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

Item
http://www.wikidata.org/entity/Q42227869
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionSusceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Achieving target voriconazole concentrations more accurately in children and adolescents.Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Successful long-term management of invasive cerebral fungal infection following liver transplantation.A new marker of echinocandins activity in an in vitro PK/PD model correlates with an animal model of Aspergillus fumigatus infection.Evolution of cross-resistance to medical triazoles in Aspergillus fumigatus through selection pressure of environmental fungicides.
P2860

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

Item
http://www.wikidata.org/entity/Q42227869
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
type
label
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
prefLabel
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Susceptibility breakpoints and ...... okinetic/pharmacodynamic model
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921